Midomafetamine
As of the edition of 20 October 2026, Midomafetamine is a small molecule: in active development; acts on SLC6A4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 85, 8 stopped early
- Disease areas
- Mental health; Chemically induced; Bones, joints and muscles; Cancer; Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | P31645 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 5 | 2 | 0 |
| Phase 1 | 34 | 24 | 7 | 2 |
| Phase 2 | 38 | 17 | 14 | 6 |
| Phase 3 | 5 | 4 | 1 | 0 |
| All trials | 85 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Maps | Lead sponsor of trials | 2020 to now |
| Resilient Pharmaceuticals | Lead sponsor of trials | 2021 to now |
| Remedy Pharmaceuticals | Lead sponsor of trials | 2021 to now |
| Definium Therapeutics | Lead sponsor of trials | 2025 to now |